pravastatin / Generic mfg. - LARVOL DELTA

A Clinical Trial to Evaluate MK-4208/TERN-701 in Healthy Adult Participants (MK-4208-001/TERN701-1014) (clinicaltrials.gov) - P1 | N=196 | Completed | Sponsor: Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

New P1 trial

Management of Lorlatinib-Induced Hyperlipidemia With PCSK9 Inhibitors: A Case Series (IASLC-WCLC 2026) - "Case Description : Case 1: A 66-year-old male on second-line lorlatinib 75 mg daily had normal baseline lipid levels but progressed to mixed hyperlipidemia refractory to pravastatin 40 mg daily, and partially improved on rosuvastatin 40 mg daily and ezetimibe 10 mg daily. After prolonged lifestyle modification attempts over four and a half years, alirocumab 75 mg/mL every 2 weeks (Q2W) was added, achieving lipid control (Figure 1)...She transitioned to evolocumab 140 mg/mL Q2W with bempedoic acid 180 mg daily with mild improvement...Conclusions : These four case reports illustrate the benefit of addition of a PSCK9i in treatment-related, refractory hyperlipidemia. PSCK9i are effective in lowering total cholesterol and LDL in patients with lorlatinib-induced hyperlipidemia and may be considered early in severe and statin-refractory cases."

Clinical • Dyslipidemia • Hypertension • Immunology • Lung Cancer • Mixed Hyperlipidemia • Musculoskeletal Pain • Non Small Cell Lung Cancer • Solid Tumor • ALK

Therapeutic Interventions for Radiation-Induced Fibrosis in Head and Neck Cancer Patients: A Systematic Review. (PubMed, Otolaryngol Head Neck Surg) - "Improvements in HNC fibrosis after current treatments ranged widely across studies; however, substantial heterogeneity in study design and outcome measurement limits definitive conclusions regarding comparative effectiveness."

Journal • Review • Aesthetic Medicine • Fibrosis • Head and Neck Cancer • Immunology • Oncology • Solid Tumor

Pravastatin Attenuates Macrophage-Rich Inflammatory Remodeling and Endothelial Glycocalyx Alteration in Kawasaki Disease-Like Vasculitis (AHA 2026) - "Abstract is embargoed at this time."

Vasculitis

Lipid-lowering agent use and changes to sleep. (PubMed, Sleep Med) - "The use of atorvastatin may be associated with negative impacts to patients' sleep, though the magnitude of change is small. Clinicians should be aware of these effects and counsel patients accordingly."

Journal • CNS Disorders • Obstructive Sleep Apnea • Respiratory Diseases • Sleep Disorder

Aggressive Lipid Lowering Therapy in ICI-Treated Melanoma (clinicaltrials.gov) - P=N/A | N=40 | Recruiting | Sponsor: University of Colorado, Denver | Not yet recruiting ➔ Recruiting

Checkpoint inhibition • Enrollment open • Atherosclerosis • Melanoma • Oncology • Solid Tumor • LAG3 • PD-L1

Statins and reporting signals for amnesia: a pharmacovigilance analysis based on adverse event reporting database. (PubMed, Front Pharmacol) - "Significant positive pharmacovigilance signals were identified for atorvastatin (n = 326, ROR = 2.82, 95% CI: 2.53-3.15, P < 0.001), simvastatin (n = 600, ROR = 4.94, 95% CI: 4.55-5.35, P < 0.001), pravastatin (n = 68, ROR = 4.77, 95% CI: 3.76-6.06, P < 0.001), and lovastatin (n = 26, ROR = 6.96, 95% CI: 4.73-10.24, P < 0.001)...This study identified significant positive pharmacovigilance signals between certain statins and amnesia. The findings of this study provide preliminary disproportionality signals regarding statin-related amnesia, offering exploratory pharmacovigilance references for subsequent safety evaluation and further pharmacoepidemiological validation."

Adverse events • Journal • CNS Disorders

Comparative risk of new-onset diabetes between pravastatin and commonly used statins: A systematic review and meta-analysis. (PubMed, Int J Risk Saf Med) - "The comparison of pravastatin versus atorvastatin (10 studies; N = 95,276 vs 490,905) yielded a pooled risk ratio (RR) of 1.01 (95% CI: 0.77-1.32; I2 = 98%). Pravastatin versus rosuvastatin (9 studies; N = 92,853 vs 114,718) yielded a pooled RR of 1.12 (95% CI: 0.85-1.47; I2 = 96%).ConclusionPravastatin did not demonstrate a lower risk of NODM when compared with atorvastatin or rosuvastatin; nevertheless, further research remains warranted."

Journal • Retrospective data • Review • Diabetes • Metabolic Disorders

Feto-maternal safety of statins in pregnancy: An updated systematic review and meta-analysis. (PubMed, Diabetes Metab Syndr) - "Statin exposure in pregnancy was not associated with increased congenital malformation risk. Potential LBW and cesarean signals, largely confined to non-pravastatin use for dyslipidaemia, warrant individualized risk-benefit assessment rather than routine use."

Journal • Retrospective data • Acute Respiratory Distress Syndrome • Cardiovascular • Diabetes • Dyslipidemia • Gestational Diabetes • Gynecology • Hypertension • Metabolic Disorders

Mechanisms and Predisposing Conditions for Statin-Induced New-Onset Type 2 Diabetes Mellitus: A Paradox Relative to Their Pleiotropic Metabolic Effects. (PubMed, Endocrinol Diabetes Metab) - "Atorvastatin, simvastatin and rosuvastatin possess the most pronounced diabetogenic properties. In contrast, lovastatin, fluvastatin, pitavastatin and most notably pravastatin exert either neutral or advantageous effects with respect to glucose metabolism."

Journal • Review • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus • CDC42 • RAC1

Statin Use and Genetically Predicted HMG-CoA Reductase Inhibition in Relation to Clonal Hematopoiesis. (PubMed, medRxiv) - "Experimentally, primary PBMCs from a DNMT3A R882 hotspot mutation carrier were cultured in methylcellulose with pravastatin or vehicle control to evaluate colony-forming dynamics...These data establish a strong rationale for prospective trials evaluating whether statins prevent the development or expansion of DNMT3A -mutant CH and its cardiovascular consequences. Given that statins are widely used with established safety profiles, affordable and have proven cardiovascular benefit, such trials are readily implementable."

Journal • Cardiovascular • Dyslipidemia • Gene Therapies • Hematological Disorders • Hematological Malignancies • Oncology • DNMT3A • TET2

Immune checkpoint inhibitor-driven smooth muscle cell phenotypic modulation: a potential contributor to atherosclerotic risk associated with these therapies. (PubMed, Front Cardiovasc Med) - "Nivolumab-induced cholesterol synthesis, PERK signaling, and SMC phenotypic modulation were reversed by neutralization and knockdown of PD-1, as well as treatment with the HMGCR inhibitor pravastatin. These results reveal that nivolumab induces HSF1-HMGCR-PERK signaling and SMC phenotypic modulation and provides a rationale for statin therapy to mitigate ICI-induced ASCVD even in normocholesterolemic patients, highlighting a potential strategy to prevent ASCVD in cancer survivors receiving ICIs."

Checkpoint inhibition • Journal • Atherosclerosis • Cardiovascular • Oncology • HSF1

Drug-Drug Interaction Signals for Major Bleeding in Nursing Home Residents: High-Throughput Screening of Clopidogrel and Oral Anticoagulants. (PubMed, Pharmacoepidemiol Drug Saf) - "SCCS screening for DDIs in NH residents identified bleeding signals for clopidogrel and oral anticoagulants, but few were mechanistically coherent and fall-related injury signals suggested residual bias."

Journal

Reversing External-beam Radiotherapy-associated Fibrosis Syndrome: an Interventional Bayesian Adaptive Randomized-controlled Orphan Drug Platform Trial for Orodental Sequelae (Reverse-fibrose) (clinicaltrials.gov) - P2 | N=250 | Recruiting | Sponsor: M.D. Anderson Cancer Center | Trial completion date: Mar 2033 ➔ Jul 2031 | Trial primary completion date: Mar 2031 ➔ Jul 2030

Trial completion date • Trial primary completion date • Fibrosis • Head and Neck Cancer • Immunology • Oncology • Solid Tumor

Association between pravastatin use and short-term mortality in ICU patients with sepsis: a retrospective propensity score-matched cohort study. (PubMed, Front Cell Infect Microbiol) - "De novo pravastatin initiation within 24 hours of ICU admission was not associated with reduced 28-day mortality. These hypothesis-generating findings warrant confirmation in future prospective studies."

Journal • Retrospective data • Acute Kidney Injury • Critical care • Infectious Disease • Nephrology • Renal Disease • Septic Shock

Older Statins Reduce Metastatic Potential in ccRCC: Mechanistic Validation of SIM (Selective Inhibitor of Metastasis) Development (KCRS 2026) - "Statins were classified as older (fluvastatin, simvastatin, lovastatin) or newer (atorvastatin, pravastatin, rosuvastatin)...These findings support further development of SIMs towards achieving metastasis-preventive therapy for ccRCC. Keywords statin, cancer metastasis, ccRCC, selective inhibitor of metastasis DOD CDMRP Funding yes"

Metastases • Clear Cell Renal Cell Carcinoma • Genito-urinary Cancer • Renal Cell Carcinoma • Solid Tumor • HIF1A

Aggressive Lipid Lowering Therapy in ICI-Treated Melanoma (clinicaltrials.gov) - P=N/A | N=40 | Not yet recruiting | Sponsor: University of Colorado, Denver

Checkpoint inhibition • New trial • Atherosclerosis • Melanoma • Oncology • Solid Tumor • LAG3 • PD-L1

Concurrent Statin Use and Overall Survival in Immune-Checkpoint Inhibitor-Treated Mucosal Head and Neck Squamous Cell Carcinoma: A Multi-Institutional Real-World Analysis (AHNS 2026) - "Adult patients with mucosal HNSCC receiving ≥1 ICI (pembrolizumab, nivolumab, durvalumab, avelumab, ipilimumab, or atezolizumab) were included...Pravastatin showed a nonsignificant trend toward lower mortality (HR 0.90; 0.81-1.01), whereas atorvastatin and simvastatin were not associated with OS... In this multi-institutional real-world cohort of nearly 23,000 mucosal HNSCC patients receiving ICIs, concurrent statin therapy did not confer a classwide survival advantage after adjustment for demographic, clinical, and tumor-related factors. However, the significant reduction in mortality observed with rosuvastatin, together with supportive findings from prior immunotherapy studies, suggests the possibility of drug-specific statin effects not captured in classwide analyses. Although exploratory, these results highlight the need for prospective and mechanistic studies to determine whether particular statin agents, dosing strategies, or tumor immune phenotypes may define..."

Checkpoint inhibition • Clinical • Real-world • Real-world evidence • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck

The impact of statins on aldosterone production in healthy adults: a randomized controlled study. (PubMed, J Endocr Soc) - "Multivariate regression analysis controlling for sex, age, race, BMI, and pretreatment angiotensin II (AngII)-stimulated ALDO showed no significant differences in 12-week posttreatment AngII-stimulated ALDO between placebo and simvastatin (P, .56; primary endpoint) nor between simvastatin and pravastatin (P, .90; secondary endpoint). Among healthy individuals on a low-sodium diet, 12-week treatment with simvastatin or pravastatin did not alter ALDO responsiveness to AngII."

Clinical • Journal • Atherosclerosis • Cardiovascular • Dyslipidemia

Complexation Process of Pravastatin With Metal Ions (Gadolinium, Nickel, Zinc) by NMR Spectroscopy. (PubMed, Magn Reson Chem) - "The DOSY NMR spectrum of pravastatin in the presence of ions (Gd3+, Ni2+, and Zn2+) revealed a change in self-diffusion coefficients compared to the parent structure. An assumption about the possible centers of localization of Gd3+ and Ni2+ ions near the pravastatin molecule has been made."

Journal • Cardiovascular • Heart Failure

Data Mining of the Japanese Adverse Drug Event Report Database and Animal Experiments for Assessment of Risks Associated With Pemafibrate. (PubMed, In Vivo) - "The JADER analysis suggests that pemafibrate may be a safer alternative to conventional fibrates, with a potentially lower association with rhabdomyolysis and acute renal failure, even when co-administered with statins. Preclinical animal experiments support the results of the JADER analysis. However, large-scale prospective studies are needed to clarify the risks of pemafibrate."

Adverse events • Journal • Acute Kidney Injury • Renal Disease

Role of organic anion transporting polypeptides in pancreatic statin disposition and islet cell function in mice. (PubMed, Drug Metab Dispos) - "After confirming islet expression, we show reduced pancreas-to-plasma distribution ratios of oral atorvastatin, rosuvastatin, and pravastatin in Oatp1a/1b knockout mice versus wildtype, and reduced insulin content in rosuvastatin-treated isolated islets which was reversed by Oatp inhibition. Hence, Oatp1a/1b are key determinants of pancreatic statin disposition and Oatp-mediated statin uptake may contribute to β-cell dysfunction."

Journal • Preclinical • Cardiovascular • Diabetes • Metabolic Disorders • Pancreatitis • ATP1A1

The endothelin-1/TLR4/NF-κB/NLRP3 inflammasome axis in preeclampsia: a review of a pathological feed-forward loop and therapeutic frontier. (PubMed, Naunyn Schmiedebergs Arch Pharmacol) - "Selective ET1_A receptor antagonists and direct NLRP3 inhibitors have shown high efficacy in reducing anti-angiogenic output and restoring maternal vascular function, while repurposed drugs like sulfasalazine and pravastatin offer immediate translational opportunities. Genetically stratified trials are now needed to identify who benefits most. However, the relative contribution of this axis varies across the clinical and genetic heterogeneity of preeclampsia, necessitating biomarker-guided trial design."

Journal • Review • Gynecology • EDN1 • ENG • IL1B • NLRP3 • TLR4

Comparative Cardiovascular, Lipid, and Safety Effects of Lipid-Modifying Therapies in Diabetes: An Agent-, Class-, and Dose-Level Network Meta-Analysis. (PubMed, Cardiovasc Drugs Ther) - "Lipid-modifying therapies were associated with beneficial and specific cardiovascular and lipid effects in diabetes. The results provide more granular and tailored lipid management strategies."

Journal • Retrospective data • Review • Cardiovascular • Diabetes • Metabolic Disorders • Myocardial Infarction

Clinical characteristics, diagnosis and prognosis of statin-induced acute pancreatitis. (PubMed, Intern Emerg Med) - "Statin-induced pancreatitis has a class effect that may be independent of duration or dosage. Clinicians should be aware of the possibility of statin-induced acute pancreatitis in order to facilitate early diagnosis and management."

Journal • Pain • Pancreatitis